Personalis (NeXT Personal) is a company within the Biotechnology category. Personalis is a cancer genomics company that provides advanced genomic sequencing and analytics for precision medicine. Its flagship NeXT Platform, particularly NeXT Personal, is designed to detect minimal residual disease (MRD) with ultra-high sensitivity by identifying a personalized signature of up to 1,800 mutations in a patient's tumor.
Personalis (NeXT Personal) was founded in 2011 and is headquartered in Menlo Park, CA.
Personalis (NeXT Personal) is rated Contender on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for Personalis (NeXT Personal) is Strong. Significant factual deltas detected.
AI models classify Personalis (NeXT Personal) as a Challenger. AI names competitors first.
Personalis (NeXT Personal) appeared in 4 of 6 sampled buyer-intent queries (67%). The brand is highly discoverable for technical genomics queries but faces stiff competition from Natera for broader 'liquid biopsy MRD' searches.
AI reliably identifies the brand as a leader in precision oncology and genomic sequencing. However, it may struggle with the most recent clinical utility data and the specific competitive advantages of NeXT Personal's ultra-high sensitivity compared to older liquid biopsy methods. Key gap: The distinction between the legacy 'ImmunoID NeXT' platform and the newer, flagship 'NeXT Personal' platform is often blurred, leading to confusion about which technology is being discussed.
Of 5 key facts verified about Personalis (NeXT Personal), 4 are well-documented (likely accurate across AI models), 1 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
Clinical trial timelines and specific sensitivity percentages for NeXT Personal, which are frequently updated in press releases but trail in general AI training data.
Buyers turn to Personalis (NeXT Personal) for Standard Pathology Monitoring: Hospital pathology departments manually performing tissue staining and analysis without personalized longitudinal monitoring., Clinical Research Agencies: Hiring specialized clinical research organizations to manage patient monitoring data manually., among 2 documented problem areas.
Buyers evaluating Personalis (NeXT Personal) typically ask AI models about "ultra-sensitive MRD testing oncology", "tumor-informed liquid biopsy companies", "whole genome cancer recurrence monitoring", and 3 similar queries.
Personalis (NeXT Personal)'s main competitors are Adaptive Biotechnologies, Foundation Medicine, Natera (Signatera). According to AI models, these are the brands most frequently named alongside Personalis (NeXT Personal) in buyer-intent queries.
Personalis (NeXT Personal)'s core products are NeXT Personal, ImmunoID NeXT, NeXT DX.
Personalis (NeXT Personal) uses Enterprise/Custom (Clinical Reimbursement).
Personalis (NeXT Personal) serves Oncologists, Biopharmaceutical Companies, Clinical Researchers.
Personalis (NeXT Personal) NeXT Personal uses a whole-genome-informed approach to track up to 1,800 mutations, offering significantly higher sensitivity than standard exome-based MRD tests.
Brand Authority Index (BAI) tier: Contender (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/personalis-next-personal
Last analyzed: April 10, 2026
Founded: 2011
Headquarters: Menlo Park, California